Atezolizumab (Tecentriq®) plus bevacizumab for the treatment of advanced or unresectable hepatocellular carcinoma (HCC). Update February 2021

Grössmann, N. (2021): Atezolizumab (Tecentriq®) plus bevacizumab for the treatment of advanced or unresectable hepatocellular carcinoma (HCC). Update February 2021. Oncology Fact Sheet Nr. 20.

[thumbnail of Oncology Fact Sheet Nr.20_Update.pdf]

Preview

PDF - Sie müssen einen PDF-Viewer auf Ihrem PC installiert haben wie z. B. GSview, Xpdf oder Adobe Acrobat Reader
78kB

Item Type:	Oncology Fact Sheet
Subjects:	QV Pharmacology, toxicology, pharmacy > QV 60-370 Pharmacology QZ Pathology > QZ 200-380 Neoplasms.Cysts WB Practice of medicine > WB 300-962 Therapeutics WI Digestive system > WI 700-770 Liver. Billary tract
Language:	English
Series Name:	Oncology Fact Sheet Nr. 20
Deposited on:	29 Oct 2020 12:35
Last Modified:	01 Feb 2021 18:28

Repository Staff Only: item control page